Kenneth Rhodes

USPTO Granted Patents = 11 (Patent Applications = 6)

EPO Patents = 1 (Patent Applications = 7)

Average Co-Inventor Count = 7.9

ph-index = 4

Forward Citations = 23(Granted Patents)

Location History:

Hopkinton, MA (US) (2010)
Belmont, MA (US) (2013 - 2024)

Company Filing History:

7 out of 2,078

Janssen Pharmaceutica Nv

patents

2 out of 3

Yumanity Therapeutics, Inc.

Years Active: 2010-2025

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12433880 - Methods for the treatment of neurological disorders (2025-10-07),

2. 12275723 - Compounds and uses thereof (2025-04-14),

3. 11873298 - Compounds and uses thereof (2024-01-16),

4. 11241417 - Compositions and methods for the treatment and prevention of neurological disorders (2022-02-08),

5. 10973810 - Methods for the treatment of neurological disorders (2021-04-13),

6. 8894999 - Use of DR6 and p75 antagonists to promote survival of cells of the nervous system (2014-11-25),

7. 8883473 - Methods of treatment using allosteric processing inhibitors for matrix metalloproteinases (2014-11-11),

8. 8798939 - Methods for designing, selecting and/or optimizing allosteric processing inhibitors for matrix metalloproteinases (2014-08-05),

9. 8753857 - Crystal structure of the pro form of a matrix metalloproteinase and an allosteric processing inhibitor (2014-06-17),

10. 8501178 - Use of DR6 and p75 antagonists to promote survival of cells of the nervous system (2013-08-06),

11. 7803793 - Heterocyclic derived metalloprotease inhibitors (2010-09-28),

Title: Innovations by Kenneth Rhodes: A Pioneer in Neurological Treatments

Introduction

Kenneth Rhodes, an innovative inventor based in Belmont, MA, has made significant contributions to the field of medicine, particularly in the treatment of neurological disorders. With a portfolio that includes nine patents, Rhodes has developed groundbreaking compounds and methods that aim to alleviate the impact of debilitating neurological conditions.

Latest Patents

Among Kenneth Rhodes' latest inventions are two notable patents focusing on compounds and their applications in treating neurological disorders. The first patent emphasizes the creation of compounds beneficial for the treatment or prevention of various neurological disorders. These compounds can be employed alone or in conjunction with other active pharmaceutical agents. The second patent delineates specific compositions and methods for addressing conditions such as amyotrophic lateral sclerosis, frontotemporal degeneration, and Alzheimer’s disease. One of the highlighted mechanisms involves administering an inhibitor of cytochrome P450 isoform 51A1, which could alter the progression of disorders linked to the aggregation of TAR-DNA binding protein (TDP)-43, ultimately aiming to improve patient outcomes.

Career Highlights

Kenneth Rhodes' career has been marked by his association with prominent companies in the pharmaceutical industry, including Janssen Pharmaceutica and Biogen Idec. His work at these institutions has been instrumental in advancing research and development in neurological therapies, showcasing his commitment to innovating healthcare solutions.

Collaborations

Throughout his career, Rhodes has collaborated with notable colleagues, including Robert Scannevin and Paul F. Jackson. These partnerships have fostered an environment for creative thinking and innovation, leading to advancements in the understanding and treatment of neurological disorders.

Conclusion

Kenneth Rhodes stands out as a significant figure in the domain of neurological research and invention. His dedication to developing effective treatments for complex conditions is reflected through his patents and collaborations with industry leaders. As the landscape of medical research continues to evolve, Rhodes' contributions are poised to leave a lasting impact on the field of neurology.

This text is generated by artificial intelligence and may not be accurate.